Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient

American Journal of Surgery

Volumn 179, Issue 2 SUPPL. 1, 2000, Pages 45-50

  Boucher, Bradley A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CILASTATIN; CIPROFLOXACIN; CLAVULANIC ACID; GENTAMICIN; IMIPENEM; MEROPENEM; MEZLOCILLIN; PIPERACILLIN; SULBACTAM; TAZOBACTAM; TICARCILLIN; TOBRAMYCIN;

ANTIMICROBIAL ACTIVITY; CONFERENCE PAPER; CRITICAL ILLNESS; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; HOSPITAL INFECTION; HUMAN; NAUSEA; NEPHROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; RASH; SURGICAL PATIENT; VOMITING;

EID: 0034055328     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(00)00321-4     Document Type: Conference Paper

References (30)

1. Hospital-acquired pneumonia in adults diagnosis, assessment of severity, initial antimicrobial therapy and preventative strategies . Am J Respir Crit Care Med. 153:1995;1711-1725.
2. Hellinger W.C., Brewer N.S. Carbapenems and monobactams imipenem, meropenem, and aztreonam . Mayo Clin Proc. 74:1999;420-434.
3. Johnson D.H., Cunha B.A. Aztreonam. Med Clinic North Am. 79:1995;733-743.
4. Nolen T.M., Phillips H.L., Hall H.J. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli. Rev Infect Dis. 7:(suppl 4):1985;S666-S668.
5. Rivera-Vazquez C.R., Ramirez-Ronda C.H., Rodiguez R.R., Saavedra S. A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections. Chemotherapy. 35:(suppl 1):1989;89-100.
6. Rodriguez J.R., Ramirez-Ronda C.H., Nevarez M.N. Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli. Antimicrob Agents Chemother. 27:1985;246-251.
7. Schentag J.J., Vari A.J., Winslade N.E., et al. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med. 78:(suppl 2A):1985;34-41.
8. Swabb E.A., Cone C.O., Muir J.G. Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections. Rev Infect Dis. 7:(suppl 4):1985;S675-S678.
9. Bjornson H.S., Ramirez-Ronda C., Saavedra S., et al. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections. Clin Ther. 15:1993;65-78.
10. Fekete T., Castellano M., Ramirez J., et al. A randomized comparative trial of aztreonam plus cefazolin versus ceftazidime for the treatment of nosocomial pneumonia. Drug Invest. 7:1994;117-126.
11. Polk H.C., Livingston D.H., Fry D.E., et al. Treatment of pneumonia in mechanically ventilated trauma patients results of a prospective trial . Arch Surg. 132:1997;1086-1092.
12. Li R.C., Zhu M., Schentag J.J. Achieving an optimal outcome in the treatment of infections the role of clinical pharmacokinetics and pharmacodynamics of antimicrobials . Clin Pharmacokinet. 37:1999;1-16.
13. Swabb E., Singhvi S., Leitz M., et al. Metabolism and pharmacokinetics of aztreonam in healthy volunteers. Antimicrob Agents Chemother. 24:1983;394-400.
14. Bristol-Myers Squibb Company. Azactam package insert. 1999.
15. McKindley D.S., Boucher B.A., Hess M.M., et al. Pharmacokinetics of aztreonam and imipenem in critically-ill patients with pneumonia. Pharmacotherapy. 16:1996;924-931.
16. Newman T.J., Dreslinski G.R., Tadros S.S. Safety profile of aztreonam in clinical trials. Rev Infect Dis. 7:(suppl 4):1985;S648-S655.
17. Moore R.D., Lerner S.A., Levine D.P. Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill nonneutropenic patients. J Infect Dis. 165:1992;683-688.
18. Weber D.J., Raasch R., Rutala W.A. Nosocomial infections in the ICU the growing importance of antibiotic-resistant pathogens . Chest. 115:(suppl 3):1999;34S-41S.
19. Yates R.R. New intervention strategies for reducing antibiotic resistance. Chest. 115:(suppl 3):1999;24S-27S.
20. Rahal J.J., Urban C., Horn D., et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 280:1998;1233-1237.
21. Rice L.B., Eckstein E.D., DeVente J., Shiaes D.M. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 23:1996;118-124.
22. Bamberger D.M., Dahl S.L. Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital. Arch Intern Med. 152:1992;554-557.
23. Quale J., Landman D., Saurina G., et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis. 23:1996;1020-1025.
24. Torres A., Aznar R., Gatell J.M., et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis. 142:1990;523-528.
25. Luna C.M., Vujacich P., Niederman M.S., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 111:1997;676-685.
26. Rello J., Gallego M., Mariscal D., et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med. 156:1997;196-200.
27. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intens Care Med. 22:1996;387-394.
28. Eisenberg J.M., Koffer H., Glick H.A., et al. What is the cost of nephrotoxicity associated with aminoglycosides. Ann Intern Med. 107:1987;900-909.
29. Fabian T.C., Boucher B.A., Croce M.C. Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury. Pharmacotherapy. 16:1996;951-957.
30. 1999 Drug Topics Red Book. Montvale, NJ: Medical Economics Company, 1999.